Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
SAN DIEGO, March 12, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova’s Advanced Lung Disease Program and Lung Transplant
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SAN DIEGO, March 05, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
In this article, we will take a look at the 12 best medical stocks to buy under $10. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Best Medical Stocks to Buy Under $10. The healthcare sector spans medical stocks including biotechnology companies, health insurance […]
Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you’re not going to get rich off of them. On the other hand, finding micro-cap stock surprises is like picking up the next Tom Brady in the final round of the NFL Draft. More often than not, your draft picks will end up being largely
SAN DIEGO, January 08, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s com
SAN DIEGO, December 13, 2023--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Ser
SAN DIEGO, December 05, 2023--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer.
SAN DIEGO, November 29, 2023--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.